The U.S. Food and Drug Administration (FDA) approved a supplemental application for Tecentriq (atezolizumab) for efficacy on April 17, 2017. This approval indicates an expansion or modification of the drug's previously approved uses, specifically concerning its demonstrated effectiveness.
Background
Atezolizumab, known commercially as Tecentriq, is an established therapeutic agent. This supplemental approval for efficacy, granted to sponsor Genentech Inc., indicates an expansion or modification of its existing approved uses, specifically concerning its demonstrated effectiveness. The approval falls under the 'Efficacy' class, affirming the drug's proven benefits.
What this means
A supplemental efficacy approval for Tecentriq (atezolizumab) means that the FDA has reviewed additional data and determined that the drug is effective for a new or expanded indication, or that new evidence supports an existing indication. This type of approval typically broadens the patient population that can benefit from the treatment or refines its use in clinical practice. Clinicians can now consider Tecentriq for this newly approved efficacy claim, which is based on the FDA's assessment of the submitted evidence. This development is important for healthcare providers seeking to optimize treatment strategies for their patients.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for supplemental application BLA 761034 S-1 for Tecentriq (atezolizumab) was documented on April 17, 2017, on the accessdata.fda.gov website, which serves as the official repository for FDA drug approval information.